Docetaxel is a chemotherapy drug commonly used to treat non-squamous non-small cell lung cancer (NSCLC) that has continued to grow despite initial chemotherapy. However, in most patients, the cancer continues to grow. The purpose of this study is to compare the effectiveness of the investigational drug BMS-936558 with docetaxel in patients with non-squamous NSCLC that has persisted despite prior therapy.
BMS-936558 boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells. BMS-936558 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells.
Patients will be randomly assigned to receive BMS-936558 or docetaxel. Each drug is given intravenously.